259 related articles for article (PubMed ID: 21393859)
1. Hunk is required for HER2/neu-induced mammary tumorigenesis.
Yeh ES; Yang TW; Jung JJ; Gardner HP; Cardiff RD; Chodosh LA
J Clin Invest; 2011 Mar; 121(3):866-79. PubMed ID: 21393859
[TBL] [Abstract][Full Text] [Related]
2. Hormonally up-regulated neu-associated kinase: A novel target for breast cancer progression.
Zambrano JN; Neely BA; Yeh ES
Pharmacol Res; 2017 May; 119():188-194. PubMed ID: 28189783
[TBL] [Abstract][Full Text] [Related]
3. Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten.
Yeh ES; Belka GK; Vernon AE; Chen CC; Jung JJ; Chodosh LA
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6103-8. PubMed ID: 23520049
[TBL] [Abstract][Full Text] [Related]
4. The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis.
Wertheim GB; Yang TW; Pan TC; Ramne A; Liu Z; Gardner HP; Dugan KD; Kristel P; Kreike B; van de Vijver MJ; Cardiff RD; Reynolds C; Chodosh LA
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15855-60. PubMed ID: 19717424
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Yeh ES; Abt MA; Hill EG
Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
[TBL] [Abstract][Full Text] [Related]
6. HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1.
Quintela-Fandino M; Arpaia E; Brenner D; Goh T; Yeung FA; Blaser H; Alexandrova R; Lind EF; Tusche MW; Wakeham A; Ohashi PS; Mak TW
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2622-7. PubMed ID: 20133759
[TBL] [Abstract][Full Text] [Related]
7. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
8. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a potent and selective HUNK inhibitor for treatment of HER2+ breast cancer.
Dilday T; Abt M; Ramos-Solís N; Dayal N; Larocque E; Oblak AL; Sintim HO; Yeh ES
Cell Chem Biol; 2024 May; 31(5):989-999.e7. PubMed ID: 38307028
[TBL] [Abstract][Full Text] [Related]
10. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.
Dong Y; Van Tine BA; Oyama T; Wang PI; Cheng EH; Hsieh JJ
Cell Res; 2014 Nov; 24(11):1354-66. PubMed ID: 25267403
[TBL] [Abstract][Full Text] [Related]
11.
Ramos-Solis N; Dilday T; Kritikos AE; Yeh ES
Biomedicines; 2022 Nov; 10(12):. PubMed ID: 36551828
[TBL] [Abstract][Full Text] [Related]
12. Developmental role of the SNF1-related kinase Hunk in pregnancy-induced changes in the mammary gland.
Gardner HP; Belka GK; Wertheim GB; Hartman JL; Ha SI; Gimotty PA; Marquis ST; Chodosh LA
Development; 2000 Oct; 127(20):4493-509. PubMed ID: 11003847
[TBL] [Abstract][Full Text] [Related]
13. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
Bhat-Nakshatri P; Sweeney CJ; Nakshatri H
Oncogene; 2002 Mar; 21(13):2066-78. PubMed ID: 11960379
[TBL] [Abstract][Full Text] [Related]
14. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.
Fereshteh MP; Tilli MT; Kim SE; Xu J; O'Malley BW; Wellstein A; Furth PA; Riegel AT
Cancer Res; 2008 May; 68(10):3697-706. PubMed ID: 18483252
[TBL] [Abstract][Full Text] [Related]
15. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.
Dankort D; Maslikowski B; Warner N; Kanno N; Kim H; Wang Z; Moran MF; Oshima RG; Cardiff RD; Muller WJ
Mol Cell Biol; 2001 Mar; 21(5):1540-51. PubMed ID: 11238891
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
18. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
20. Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase.
Zambrano JN; Williams CJ; Williams CB; Hedgepeth L; Burger P; Dilday T; Eblen ST; Armeson K; Hill EG; Yeh ES
Oncotarget; 2018 Nov; 9(89):35962-35973. PubMed ID: 30542510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
